The importance of miRNA-630 in human diseases with an especial focus on cancers

Sepideh Kadkhoda¹ and Soudeh Ghafouri-Fard²*

Abstract

miR-630 is encoded by MIR630 gene (NC_000015.10) on 15q24.1. This miRNA is mostly associated with cytokine signaling in immune system. Several neoplastic as well as non-neoplastic conditions have been linked with dysregulation of miR-630. It is an oncogenic miRNA in renal cell carcinoma, multiple myeloma, colorectal cancer, acute lymphoblastic leukemia, ovarian cancer and prostate cancer. On the other hand, it is a putative tumor suppressor miRNA in lung, cervical, breast, thyroid and esophageal tissues. In a number of other tissues, data regarding the role of miR-630 in the carcinogenesis is conflicting. Expression levels of miR-630 can be used as markers for prediction of cancer course. Moreover, miR-630 can influence response to chemoradiotherapy. This miRNA is also involved in the pathoetiology of IgA nephropathy, obstructive sleep apnea, age-related nuclear cataract and vitiligo. In the present review, we discuss the role of miR-630 in these conditions.

Keywords: miR-630, Cancer, Marker

Introduction

MicroRNAs (miRNAs) are small sized transcripts with no capacity of protein coding [1]. miRNAs can bind to coding sequences and miRNA seeds in coding regions are coordinated with regulation/influencing the targets [2–4]. Moreover, various molecular techniques like reporter assays confirms that miRNA seeds in coding region can be functional and influence the protein synthesis [5, 6]. Mature miRNAs have sizes about 22 nucleotides and are made from their precursors in a multistep process being catalyzed by Drosha and Dicer RNase III proteins. These transcripts serve as guide molecules for suppression of expression of target RNAs. Since they can target the majority of protein-coding RNAs, miRNAs partake in virtually total physiological and pathological events. miRNA synthesis is tightly controlled in terms of time and location. Not surprisingly, dysregulation of expression of miRNAs is linked with the pathoetiology of several human diseases, above all being cancer [7]. miR-630 is an example of these transcripts which is encoded by MIR630 gene (NC_000015.10) on 15q24.1. This miRNA is mostly associated with cytokine signaling in immune system. Moreover, this miRNA has functional interactions with other non-coding RNAs such as long non-coding RNAs and circular RNAs. Thus, it contributes in the construction of a complex interactive network that is implicated in the pathogenesis of human disorders. Several neoplastic as well as non-neoplastic conditions such as IgA nephropathy, obstructive sleep apnea, cataract, vitiligo and heterotopic ossification have been linked with dysregulation of miR-630. In malignant conditions, both high throughput sequencing methods and candidate gene expression analyses have confirmed association between dysregulation of miR-630 and disease progression. Although there are several miRNAs that play important roles in the pathogenesis of disorders, we have selected miR-630 with respect to being targeted by important upstream factors such as long non-coding RNA H19 and also targeting several important genes and participation in key signaling pathway such as AKT, P53, TGFB-ERK/SP1, JNK/c-Jun, PI3K/AKT and JAK2/
miR-630 has been found to be over-expressed in renal cancer cell lines compared with HK-2 normal renal cells. Inhibition of miR-630 has resulted in suppression of proliferation, migratory aptitude, and invasiveness of 786-O renal cancer cells. Moreover, apoptosis has been induced following miR-630 inhibition, indicating potential of this method for treatment of renal cancer [8]. miR-630 has also been shown to promote proliferation of HCT116 colorectal cancer cells and inhibit their apoptosis. The impact of miR-630 on apoptosis of HCT116 cells has also been verified through the observed reduction of expressions of p27, BAX (BCL2 Associated X), procaspase-3 and active caspase-3. Moreover, miR-630 has enhanced levels of phosphorylated-AKT and BCL2 (B-Cell CLL/ Lymphoma 2). Thus, miR-630 has an oncogenic role in colorectal cancer through modulation of p27 and AKT pathway [9]. In Jurkat cell line, miR-630 has induced cell proliferation and reduced cell apoptosis through affecting expressions of p53, p21 and BCL2 [10]. Expression of miR-630 has been reported to be increased in epithelial ovarian cancer tissues as compared with normal ovarian tissues. In SKOV3 cells, miR-630 up-regulation has shown pro-proliferative and pro-migratory effects, at least partly through targeting KLF6 (Krüppel-like Factor 6) [11]. Moreover, miR-630 has been shown to affect cell apoptosis and sensitivity of ovarian cancer cells to cisplatin through targeting PTEN (Phosphatase and Tensin Homolog) [12]. In a high throughput study using PCR array and NanoString techniques, miR-630 has been found to be among up-regulated miRNAs in tumoral tissues of young patients compared to normal tissues [13]. In hepatocellular carcinoma (HCC), two different studies have reported contradictory results regarding the role of miR-630. Zhang et al. have shown over-expression of miR-630 in HCC samples and cell lines compared with corresponding controls [14]. miR-630 expression has been found to be significantly elevated at advanced TNM stages [14]. Furthermore, up-regulation of miR-630 in tissue samples of HCC has been associated with elevation in serum levels of AFP (Alpha Fetoprotein), indicating its association with HCC progression [14]. On the other hand, Chen et al. have reported that down-regulation of miR-630 in HCC patients is associated with higher chance of tumor recurrence and shorter survival of patients [15]. Functionally, miR-630 has been shown to attenuate epithelial-mesenchymal transition (EMT) in HCC through targeting Slug [15]. Moreover, TGF-β (Transforming Growth Factor Beta 1)-Erk (Extracellular Signal-Regulated Kinase)/SP1 (Specificity Protein 1) and JNK (Jun N-Terminal Kinase)/c-Jun cascades have been demonstrated to repress transcription of miR-630 via taking the position of transcription factors on promotors. Forced over-expression of miR-630 has reinstated the TGF-β-associated EMT [15]. In non-small cell lung cancer (NSCLC), circMTDH.4 has been shown to regulate expression of AEG-1 (Astrocyte Elevated Gene-1) oncogene through sequestering miR-630 [16]. CircMTDH.4 silencing or miR-630 up-regulation has suppressed resistance of NSCLC cells to chemo/radiotherapy, indicating the importance of circMTDH.4/miR-630/AEG-1 axis in modulation of response of NSCLC cells to these therapeutic options [16]. According to colony formation assays, suppression of circ-circMTDH.4 with sh-circMTDH.4 or/miR-630 up-regulation by miR-630 mimic significantly increased 5-FU or cisplatin-induced cell death in A549 cells [16]. Consistent with this study, miR-630 has been found to be down-regulated in NSCLC tissues and cells [17]. Forced up-regulation of miR-630 could suppress proliferation, migration, and invasiveness of NSCLC cells through targeting LMO3 (LIM Domain Only 3), a gene that encodes a nuclear LIM-only protein [17]. miR-630 acts as up-stream regulator for LMO3 [17]. Restoration of LMO3 significantly reversed the anti-cancerous effects of miR-630 on cell proliferation, migration, and invasion in malignant cells. So, miR-630 inhibited the proliferation, migration, and invasion of NSCLC cells by down-regulation of LMO3 level [17]. Expression of miR-630 has been shown to be decreased in serum of gastric cancer patients compared with controls [18]. Notably, levels of miR-630 have been much lower in those having aggressive tumors [18]. Down-regulation of miR-630 has been correlated with poor prognosis of these patients [18]. The tumor suppressor role of miR-630 in gastric cancer has been further verified through the observed reduction in proliferation ability of SGC-7901 cells following over-expression of this miRNA [18]. Functionally, miR-630 exerts these effects through down-regulating expression of SOX4 (SRY-Box 4) [18]. Conversely, in a study conducted by Zhang et al., expression of miR-630 has been reported to be higher in gastric cancer tissues (intestinal, mixed, and diffuse types) compared to corresponding nearby tissues [19]. The tumor suppressor circular RNA circRNA_100269 has been shown to suppress growth of gastric cancer cells through targeting miR-630 (Fig. 1) [19]. Finally, Feng et al. have reported that miR-630 suppresses EMT, migration and invasive features of gastric cancer cells through regulating FoxM1 (Forkhead Box M1) and decreasing expressions of GTP-Rac1, p-PI3K (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and p-AKT [20].
the cells treated with TGF-β, miR-630 via blocking of vimentin, slug, snail, and N-cadherin and also by induction of β-catenin, E-cadherin, wnt3a, and wnt5a inhibited cell viability, migration, invasion, and EMT (Fig. 1) [21].

Thus, this miRNA has a role in modulation of canonical Wnt signaling [21].

In nasopharyngeal carcinoma (NPC), miR-630 has been up-regulated in serum samples of patients compared with controls, indicating a biomarker role for this miRNA [22]. On the other hand, its expression has been shown to be down-regulated in NPC samples compared with chronic inflammatory nasopharyngeal epithelium. Functionally, H19 through sponging miR-630 could regulate invasiveness of these cells [23]. Table 1 summarizes the role and expression pattern of miR-630 in cancers.

Expression levels of miR-630 could affect patients’ prognosis. In renal cell carcinoma, its expression has been correlated with tumor grade, lymph node metastasis, as well as distant metastasis [33]. In NSCLC, low level of miR-630 and high level of BCL2 have predicted poor outcomes in the patients [34]. In HCC, miR-630 up-regulation has been correlated with advanced stage, micro and macro-vascular invasion in a single study [14], while in another study its down-regulation has been associated with high metastasis probability, incomplete encapsulation, high tumor number, and vascular invasion possibility [15]. In gastric cancer, Zhou et al. [18] and Chu et al. [35] have reported totally contradicted results. Table 2 summarizes the impact of miR-630 expression on patients’ survival in different types of cancers.

miR-630 has also been found to affect response of cancer cells to chemo/radiotherapy. Pre-miR-630 has been shown to decrease cisplatin (CDDP)-induced cell death in NSCLC cells. Pre-miR-630 could modulate

---

**Fig. 1** In gastric cancer, circRNA-100269 had a negative correlation with miR-630 and inhibited its expression (blue axis) [19]. In the cells treated with TGF-β, miR-630 via blocking of vimentin, slug, snail, and N-cadherin and also by induction of β-catenin, E-cadherin, wnt3a, and wnt5a inhibited cell viability, migration, invasion, and EMT (red axis) [21]. Moreover, miR-630 through inhibition of SOX4 could suppress invasion and proliferation of gastric cancer cells (purple axis) [18].

---

**Table 1** Role and expression pattern of miR-630 in cancers.

**Table 2** Impact of miR-630 expression on patients’ survival in different types of cancers.
Table 1 miR-630 in cancers (ANCT adjacent non-cancerous tissue, GEO gene expression omnibus)

| Type of cancer                  | Expression pattern | Samples                                                                 | Cell lines                                                                 | Downstream targets                                | Other related molecules and pathways               | Function                                                                                     | Refs. |
|---------------------------------|--------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------|--------------------------------------------------|---------------------------------------------------------------------------------------------|-------|
| Renal cell carcinoma (RCC)      | Up                 | –                                                                       | 786-O, ACHN, Caki-1, Caki-2 and HK-2                                      | –                                                 | –                                                | Inhibition of miR-630 could suppress tumorigenesis                                         | [8]   |
| Multiple myeloma (MM)           | Up                 | Plasma from 40 MM patients and 20 control subjects                      | –                                                                         | –                                                 | –                                                | miR-630 was categorized as a differentially expressed miRNA between MM patients and healthy subjects | [24]  |
| Colorectal cancer (CRC)         | –                  | –                                                                       | HCT116                                                                    | P27, BAX and caspase-3, p-AKT and BCL2           | AKT pathway                                      | Overexpression of miR-630 via inhibiting of P27, BAX and caspase-3 and enhancing p-AKT and BCL2 could increase cell proliferation and immortality. Suppression of it could have an opposite effect | [9]   |
| Acute lymphoblastic leukemia (ALL)| –                 | –                                                                       | Jurkat cells                                                              | P53, P21, and BCL2                                | PS3 pathway                                     | Overexpression of miR-630 by suppressing P53 and p21 and via bcl2 enhancement could lead to the growth of cancer cells and inhibition of the apoptosis process | [10]  |
| Ovarian Cancer (OC)             | Up                 | 30 ovarian cancer tissues, 30 normal ovarian tissues/mice               | SKOV3                                                                     | KLF6                                             | –                                                | Overexpression of miR-630 could enhance tumorigenesis                                        | [11]  |
| Prostate cancer (PCa)           | Up                 | 10 pairs of PCa Tumors and ANCTs from young men                         | –                                                                         | –                                                 | –                                                | miR-630 up-regulated in young men tumor tissues than their normal adjacent tissues             | [13]  |
| Hepatocellular carcinoma (HCC)  | Up                 | 42 pairs of tumors and ANCTs                                            | SMMC-7721, Hep3B, HepG2, HCCLM3, LO2 and HL-7702                         | AFP                                              | –                                                | A direct correlation between AFP level and miR-630 expression could be observed               | [14]  |
| –                               | –                  | –                                                                       | OSG7701, HL-7702, HCCLM3, MHCC97H, MHCC97L, SMMC-7721, HLF, Bel7402, HepG2, Hep3B and Huh7 | Slug, E-cadherin, N-cadherin, and vimentin       | TGF-β-ERK/SP1 and JNK/c-Jun                      | miR-630 could diminish cell migration, invasion, and EMT and also afford apoptosis. TGF-β by ERK/SP1 and JNK/c-Jun pathways could inhibit miR-630 | [15]  |
| Pancreatic cancer (PC)          | –                  | GEO database                                                            | –                                                                         | NTS, CDH2, GRIA2                                 | PI3K/AKT                                         | miR-630 could promote apoptosis by affecting PI3K/AKT pathway                                | [25]  |
| Type of cancer | Expression pattern | Samples | Cell lines | Downstream targets | Other related molecules and pathways | Function | Refs. |
|----------------|-------------------|---------|------------|-------------------|--------------------------------------|----------|------|
| Non-small cell lung cancer (NSCLC) | Down | 22 pairs of NSCLC tissues and ANCTs | NCI-H23, A549, H157, H1299 and 16HBE | LMO3 | – | The expression level of miR-630 could have an opposite correlation with LMO3, and its overexpression could suppress tumorigenesis | [17] |
| Cervical cancer (CC) | Down | 10 pairs of cervical tumors and ANCTs | Caski, M571, Hela and Siha | Vimentin, N-cadherin, E-cadherin, Snail, Zeb1 and Zeb2 | E6/E7-p53 signaling pathway | E6/E7 by inhibition of p53 could suppress miR-630 that provokes invasion, migration, and EMT of cancer cells | [26] |
| | Down | Mice | Caski, HeLa, C-33A, SiHa, SW756, and HcerEpic | YAP1 | LncRNA NOC2L-4.1 | NOC2L-4.1 by regulation of miR-630/YAP1 axis could promote cell multiplication and migration. NOC2L-4.1 and YAP1 had an inverse correlation with miR-630 | [27] |
| Breast cancer (BC) | Down | 43 pairs of tumor tissues and ANCTs | MDA-MB-231-luc-D3H2LN, MCF-10A, MDA-MB-231, MDA-MB-468, MDA-MB-435S, BT-549, BT-474, SK-BR-3, HCC1937, MCF7, and HEK293T | MTDH | – | Over-expression of miR-630 could prevent cell migration, invasion, colony formation, and pulmonary metastasis | [28] |
| Gastric cancer (GC) | Down | Blood, tumor tissue and ANCTs from 131 patients/ blood sample from 116 healthy persons | SGC-7901 | SOX4, p21, p27, MMP2, and MMP9 | – | Over-expression of miR-630 and as a result decreased expression of SOX4 could reduce proliferation and invasion of cells | [18] |
| | Up | 167 pairs of tumors and ANCTs | AGS, MKN28, MKN45, BGC823, MGC803, SGC7901, and GE51 | – | CircRNA-100269 | miR-630 as a target of circRNA-100269 could have a negative correlation with this circular RNA. So, it could reverse the inhibitory effects of circRNA-100269 | [19] |
| | – | – | SGC-7901 | FoxM1, Ecadherin, vimentin, GTP-Rac1, p-PI3K, and p-AKT | Ras/PI3K/AKT | miR-630 could cause migration, invasion, and EMT decline | [20] |
| Nasopharyngeal carcinoma (NPC) | Up | Plasma sample from 55 NPC patients and 45 controls | – | – | – | miR-630 could be considered as a new biomarker in NPC | [22] |
| | – | – | NR69, CNE2, CNE1, and HONE1 | EZH2, E-cadherin | H19 | H19 as a sponge for miR-630 could regulate EZH2 and led to cell invasion | [23] |
Table 1 (continued)

| Type of cancer                          | Expression pattern | Samples                                                                 | Cell lines                        | Downstream targets         | Other related molecules and pathways | Function                                                                                                           | Refs. |
|-----------------------------------------|--------------------|-------------------------------------------------------------------------|-----------------------------------|-----------------------------|--------------------------------------|--------------------------------------------------------------------------------------------------------------------|-------|
| Osteosarcoma                            | Down               | 147 pairs of tumor tissues and ANCTs                                    | Saos-2, U2OS, MG63, HOS and hFOB1.19 | PSMC2, N-cadherin and vimentin | –                                    | miR-630 as an upstream tumor suppressor factor of PSMC2 could inhibit tumor characteristics                        | [29]  |
| Papillary thyroid carcinoma (PTC)       | Down               | 47 pairs of PTC tissues and ANCTs/GEO database                         | Nthy-ori3-1, SW1736, 8505C and TPC-1 | Caspase3, caspase9, vimentin, N-cadherin, p-JAK2 and p-STAT3 | JAK2/STAT3                              | Up-regulation of miR-630 could inhibit proliferation, invasion, and migration processes and could cause apoptosis | [30]  |
| Esophageal cancer                       | Down               | Peripheral blood from 58 EC patients and 60 controls                  | KYSE-150, KYSE-450, ECA109 and HEEC | –                           | –                                    | miR-630 induction in malignant cells could inhibit migration and invasion                                          | [31]  |
| Esophageal squamous cell carcinoma (ESCC)| Down              | 44 pairs of tumors and ANCTs/mice                                     | Eca109, EC9706, TE1, Kyse-30, Kyse-70 and HEEC | E-cadherin, β-catenin N-cadherin, slug and vimentin | –                                    | miR-630 upregulation could suppress proliferation, metastasis, EMT, and invasion of cells                        | [32]  |
| Samples | Kaplan Meier | Multivariate Cox analysis | Refs. |
|---------|-------------|--------------------------|-------|
| 33 renal cell carcinoma (RCC) tissues | – | Up-regulation of miR-630 was correlated with TNM stage class I | [36] |
| 92 RCC tissues | Up-regulation of miR-630 was correlated with the unfavorable prognosis of patients | Up-regulation of miR-630 was correlated with the grade, lymph node metastasis, and distant metastasis | [33] |
| 53 ovarian cancer (OC) tissues | – | High level of miR-630 was correlated with higher stages and lymph node metastasis | [12] |
| 114 tumor tissues of non-small cell lung cancer (NSCLC) | Low level of miR-630 and high level of BCL2 correlated with weak outcomes in the patients | The advanced stage of tumors was associated with low level of miR-630 | [34] |
| 42 pairs of hepatocellular carcinoma (HCC) tumors and ANCTs | There was a positive correlation between miR-630 expression and the patient's prognosis | There was a positive correlation between miR-630 expression and advanced stage (II–III), micro and macro-vascular invasion | [14] |
| 97 HCC patient tissues | Low level of miR-630 was associated with the poor prognosis | There was a correlation between low levels of miR-630 with metastasis probability, incomplete encapsulation, advanced edmondson stage, advanced TNM stage, advanced BCLC stage, high tumor number, and vascular invasion possibility | [15] |
| 46 NSCLC tumor samples | Low level of miR-630 was correlated with a worse prognosis | Low level of miR-630 usually observed in advanced stages (II, III, and IV) | [37] |
| Tumor tissue from 118 gastric cancer (GC) patients | Low level of miR-630 was associated with the poor prognosis | There was correlation between miR-630 expression with tumor size, lymph node metastasis, depth of invasion, and stage | [18] |
| 236 GC tumors (intestinal and diffuse type) | miR-630 up-regulation was associated with poor overall survival | miR-630 over-expression correlated with invasion, lymph node and distant metastasis, and TNM stage | [35] |
| 147 osteosarcoma tissues | Low level of miR-630 was associated with the worse prognosis | There was a correlation between low miR-630 expression with higher stage and distant metastasis | [29] |
| Peripheral blood from 58 esophageal cancer patients | Low level of miR-630 was associated with poor prognosis | The levels of miR-630 were associated with disease course, stage, differentiation degree, and metastasis | [31] |
| 44 esophageal squamous cell carcinoma (ESCC) tumors | Low level of miR-630 was associated with the unfavorable prognosis | The levels of miR-630 were associated with tumor range, lymphatic metastasis, and stage | [32] |
| 116 pairs of bladder urothelial carcinoma and ANCTs, 42 normal tissue | High level of miR-630 was associated with the worse prognosis | There was a correlation between high miR-630 level with advanced TNM stage, higher grade and, lymph node metastasis | [38] |
| 206 colorectal cancer (CRC) | High miR-630 expression was associated with poor overall survival | High expression of miR-630 correlated with tumor invasion (T3+T4), lymph node metastasis, distant metastasis, and advanced TNM stage | [39] |
several phase of the intrinsic pathway of apoptosis, such as oligomerization of BAX, dissipation of transmembrane potential in the mitochondria, and processing of caspases-9 and 3. Furthermore, pre-miR-630 has been found to obstruct early signs of the DNA damage responses, such as ATM (Ataxia Telangiectasia Mutated) phosphorylation (Fig. 2) [40].

In renal cancer cells, miR-630 up-regulation has been found to inhibit uptake of oxaliplatin by cancer cells through targeting organic cation transporter OCT2 (Organic Cation Transporter 2) [36]. On the other hand, expression of miR-630 has been demonstrated to be associated with higher response of colon cancer cells to radiotherapy. miR-630 has been shown to induce apoptosis

![Diagram](https://via.placeholder.com/150)

**Fig. 2** In non-small cell lung cancer (NSCLC) cells were treated with cisplatin (CDDP), miR-181a promoted cell death via BAX oligomerization and enhancement of procaspase-3 and procaspase-9 maturation, but miR-630 had an opposite effect. Also, miR-630 via blocking phosphorylation of ATM, H2AX, and P53 inhibited apoptosis. Moreover, miR-630 through enhancement of p27 expression, promoted cell cycle arrest in G0/G1 resulting in significant decrease in sensitivity to CDDP [40].
in these cells following ionic radiation through targeting BCL2L2 (BCL2 Like 2) and TP53RK (TP53 Regulating Kinase). Moreover, CREB (CAMP Responsive Element Binding Protein 1) could regulate expression of miR-630, and demethylation could enhance expression of miR-630 [41]. In ovarian cancer cells, miR-630 inhibition could increase sensitivity to cisplatin [12], decline cell proliferation, invasion, and motility and improves apoptosis and sensitivity to paclitaxel [42]. miR-630 has also been shown to target IGF1R (Insulin Like Growth Factor 1 Receptor) to influence response of breast cancer cells to HER2-targeting agents [43]. Finally, in 4-aminobiphenyl-treated HCC cells, the level of miR-630 has been increased, leading to suppression of genes involved in DNA repair [44]. Table 3 shows the effect of miR-630 in the response of tumor cells to chemotherapy, radiotherapy and carcinogens.

In lung cancer cells after DNA damage, miR-630 could inhibit proliferation and promote apoptosis by CDC7 (Cell Division Cycle 7) targeting, but so it could suppress apoptosis via other targets. In other words, miR-630 could have dual effect on apoptosis process and this issue goes back to its downstream targets [45].

According to Rupaimoole et al. study, in ovarian and breast cancer cell lines, hypoxia condition led to miR-630 enhancement and targeting of Dicer by this miRNA [49]. This approach caused more tumor growth and metastasis. Moreover, the level of miR-630 expression affected the overall survival of patients, so that in patients who had a higher level of this miRNA, overall survival was more unfavorable [49]. The participation of miR-630 in various signaling pathways in different malignancies was shown in Fig. 3.

miR-630 in non-malignant conditions

Expression of miR-630 has also been appraised in the context of non-neoplastic conditions (Table 4). For instance, this miRNA has been found to be up-regulated in human milk exosomes of HIV (Human Immunodeficiency Virus)-1 infected mothers compared with uninfected controls [50]. Differentially expressed miRNAs between these two groups have been enriched in pathways related with cell cycle transition, cancer, TGF-β pathway, FoxO pathway, fatty acid biosynthesis, p53 pathway and apoptosis [50]. Besides, the area under receiver operating characteristics curve of miR-630 has been measured to be 0.82, indicating its potential to detect HIV-1 infection in mothers [50]. In another study, miR-630 has been identified as a putative biomarker for prediction of AIDS (Acquired Immunodeficiency Syndrome) progression [51]. A high throughput method has shown down-regulation of miR-630 levels in palatal tonsils from IgA nephropathy patients compared with chronic tonsillitis. miR-630 has been shown to decrease expression of TLR4 (Toll-like Receptor 4), thus reducing levels of secreted IgA1 and increasing galactosylation of the IgA1 hinge region. Furthermore, TLR4 can influence expression levels of IL (Interleukin 1)-1β and IL-8 via NF-κB signaling to control both IgA1 levels and its glycosylation [52]. miR-630 has also been among miRNAs whose expressions have been correlated with the severity of nuclear opacity in age-related nuclear cataract [53]. This miRNA has been found to regulate expression of MAPK14 (Mitogen-Activated Protein Kinase 14) and a number of other genes [53].

Discussion

miR-630 has different gene targets among them are those associated with cancer phenotype such as BCL2 [50], YAP-1 [27] and Slug [15]. Expression of this miRNA has been best assessed in the context of malignant conditions. However, the results of conducted studies in this field are contradictory. It is an oncogenic miRNA in renal cell carcinoma [8], multiple myeloma [24], colorectal cancer [9], acute lymphoblastic leukemia [10], ovarian cancer [11] and prostate cancer [13]. On the other hand, it is a putative tumor suppressor miRNA in lung [17], cervical [26], breast [28], thyroid [30] and esophageal tissues [31]. In a number of other tissues, data regarding the role of miR-630 in the carcinogenesis is conflicting [18, 19].

Circulating levels of miR-630 can be used as marker for separation of cancer patients from controls [22]. Moreover, expression profile of this miRNA has the potential to predict course of malignancy in several types of cancers (summarized in Table 2).

In addition, miR-630 can affect response of cancer cells to ionizing radiation, oxaliplatin and cisplatin. Thus, prior identification of miR-630 levels in tumoral tissues or circulation of patients might help in choosing the best efficient anticancer regimen in a personalized manner.

miR-630 is functionally linked with AKT, P53, TGFβ-ERK/SP1, JNK/c-Jun, PI3K/AKT and JAK2/STAT3 pathways which are among the mostly dysregulated pathways in cancers. Similar to other miRNAs, miR-630 has functional interactions with other classes of non-coding RNAs including long non-coding RNAs and circRNAs. H19, circMTDH.4 and circRNA_100269 are among transcripts whose interactions with miR-630 have been verified so far. High throughput evaluation of expression profiles of different classes of RNAs and additional functional analyses are needed for identification of other interacting molecules with miR-630.
| Type of cancer                     | Expression pattern | Samples                                                                 | Cell lines                                                                 | Target       | Related molecules and pathways                                                                 | Function                                                                                           | Refs. |
|-----------------------------------|--------------------|------------------------------------------------------------------------|----------------------------------------------------------------------------|--------------|-----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-------|
| Renal cell carcinoma (RCC)        | Up                 | 15 pairs of RCC and ANCTs/mice                                         | 786-Q, 769-P, HEK-293                                                     | OCT2         | C-Myc                                                                                         | miR-630 is up-regulated by C-Myc and by suppression of OCT2 cause oxaliplatin resistance          | [36]  |
| Colorectal cancer (CRC)           | –                  | –                                                                      | Ls174T, SW480, HCT116, SW837, HR8348, and HT29                            | BCL2L2, TP53RK, caspase3, caspase6 | CREB                                                                                         | High expression of miR-630 was positively associated with the radiosensitivity and apoptosis        | [41]  |
| Ovarian cancer (OC)               | Up                 | 53 cancerous, 25 benign, and 20 normal tissues                        | A2780 and SKOV3                                                          | PTEN         | –                                                                                             | miR-630 inhibition could suppress proliferation, invasion, migration of cancer cells, and promote cell death and sensitivity to cisplatin | [12]  |
|                                  | Up                 | Mice                                                                  | SKOV3-TR and SKOV3                                                        | APAF-1       | –                                                                                             | miR-630 inhibition could decline proliferation, invasion, and motility of cells and improves apoptosis and sensitivity of cells to paclitaxel | [42]  |
| Non-small cell lung cancer (NSCLC)| –                  | –                                                                      | CL1-Q,TL-4, A549, H1299, H23, H358                                       | BCL2         | –                                                                                             | A low level of miR-630 and a high level of BCL2 were correlated with poor response to cisplatin drug and colony formation | [34]  |
|                                  | Down               | –                                                                      | BEAS-2B, NCI-H1650, NCI-H358, HCC827, NCI-1299 and A549                  | AEG-1        | CircMTDH4                                                                                  | CircMTDH4 via miR-630/AEG-1 axis regulation could promote proliferation, invasion, metastasis, and resistance to chemotherapy and radiotherapy | [16]  |
|                                  |                    |                                                                        | A549, H1650, H1975, HCC827, HCT116, HeLa                                 | BAX, Caspase3, caspase9, ATM, P3, p-p3, H2AX, P27                         | PS3 pathway, mitochondrial apoptotic pathway                                                     | miR-630 transfection to malignant cells could lead to low sensitivity to cisplatin                | [40]  |
|                                  |                    | Mice                                                                  | PC9, PC9GR, CL97, H1 975, H1650 and HCC827                              | YAP1, p-ERK, slug, Bad, and Bcl-2                                          | ERK, SP1                                                                                     | In EGFR-mutated lung cancer cells, miR-630/YAP1/ERK axis may be responsible for TKI resistance | [37]  |
| Lung cancer                       | –                  | –                                                                      | A549 and H1 299                                                          | –            | E2F1, DROSHA                                                                                 | In cells treated with cisplatin, E2F1 via DROSHA enhancement could increase miR-630 expression   | [45]  |
| Type of cancer          | Expression pattern | Samples                  | Cell lines                                                                 | Target             | Related molecules and pathways | Function                                                                                       | Refs. |
|------------------------|--------------------|--------------------------|----------------------------------------------------------------------------|--------------------|-------------------------------|---------------------------------------------------------------------------------------------|-------|
| Prostate cancer (PCa)  | –                  | –                        | PC-3, LNCaP, MDA-MB231, MCF-7, U2OS, and HeLaS3                           | –                  | –                             | Treatment of cells with gefitinib and luteolin could lead to growth suppression via miR-630 induction and GAK reduction | [46]  |
| Pancreatic cancer (PC) | –                  | –                        | PANC-1 and MiaPaCa-2                                                      | IGF1R              | –                             | Treatment of cells with 3-Cl-AHPC led to miR-630 over-expression which in turn reduced IGF1R and induced cell death | [47]  |
| Hepatocellular carcinoma (HCC) | – | – | HepG2                                                   | RAD18              | DNA repair pathway            | In 4-aminobiphenyl-treated cells, the level of miR-630 was increased, leading to suppression of genes involved in DNA repair | [44]  |
| Breast cancer (BC)     | Down               | GEO database              | SKBR3, HCC1954 and MDA-MB-453                                            | IGF1R, HER2, and EGFR | –                             | In drug resistant HER2-positive breast cancers, miR-630 could lead to greater effectiveness of chemotherapy drugs and reduced aggressive state of cells | [43]  |
| Glioma                 | –                  | Mice                     | BT325, U373, U87 and U251                                                 | CDC14A             | –                             | miR-630 inhibition via CDC14A up-regulation could promote cell proliferation and radioresistance | [48]  |
Conclusion
Cumulatively, miR-630 is involved in the pathoetiology of several malignant and non-malignant conditions. Yet, its role in the carcinogenesis is so complicated that it is not possible to assign a tumor suppressor or oncogene role for it in all tissue contexts. In spite of the presence of vast body of literature on the role of this miRNA in malignant conditions, few studies have addressed its contribution in non-malignant conditions. Among non-malignant conditions, the pathogenesis of IgA nephropathy, obstructive sleep apnea, age-related nuclear cataract, vitiligo and heterotopic ossification is related with levels of miR-630. Moreover, this miRNA has been found in exosome secreted in the human milk, possibly reflecting the disease status of the mother. This miRNA can be used as a potential biomarker for cancerous conditions. However, since its levels are different in diverse malignancies, it can be better used for patients’ follow-up rather than initial diagnosis. The presence of this miRNA in exosomes potentiates its applications in non-invasive diagnostic methods. However, future studies are necessary for validation of this hypothesis. A major limitation of studies that assessed the diagnostic or prognostic impact of miR-630 in human disorders is lack of validation in independent cohorts.

Fig. 3 Participation of miR-630 in various signaling pathways in different malignancies. PC pancreatic cancer, CRC colorectal cancer, ALL acute lymphoblastic leukemia, PTC papillary thyroid carcinoma, HCC hepatocellular carcinoma, GC gastric cancer, CC cervical cancer
| Type of disease | Expression pattern | Samples | Cell lines | Downstream targets | Related molecules and pathways | Function | Refs. |
|----------------|-------------------|---------|------------|-------------------|-------------------------------|----------|------|
| AIDS           | Up                | 27 HIV-1 positive women, 9 HIV-1 negative women | –          | BCL2, BCL2L2, BCL2L11, and YAP1 | –                | miR-630 could be considered as a distinguishing biomarker between HIV-1-infected mother milk and non-HIV-1-infected mother milk | [50] |
|                |                   |         |            |                   |                               |          |      |
|                |                   | Upper in chronic progressors than others | 13 uninfected controls, 12 chronic progressors and 12 long-term nonprogressors (GEO dataset) | PEL11, LAPTMS5, EXO1, ZNF131, TMED7 | Enzyme linked receptor protein and receptor guanylyl cyclase signaling pathways | miR-630 could be considered as a putative biomarker for AIDS progression | [51] |
| IgA nephropathy (IgAN) | Down            | 27 tonsil tissues from IgAN patients and 20 tonsil tissues from patients with chronic tonsillitis | Tonsil mononuclear cell (TMC) | TLR4, IgA1 | NF-κB signaling pathway | Over-expression of miR-630 caused TLR4 and IgA1 attenuation while glycosylation content of IgA1 was enhanced | [52] |
| Obstructive sleep apnea (OSA) | Down in ED      | 128 children: OBNEF (n = 23), OBED (n = 20), OSA (n = 34), OSA (n = 25), and Control (n = 26)/mice | Microvascular endothelial cells | 416 different genes | 10 various pathways as tight junction signaling pathways, NRF2-mediated oxidative stress responses and AMP kinase | miR-360 could be postulated as a risk factor of cardiovascular disease in OSA and obesity in children | [54] |
| Age-related nuclear cataract | Up              | 45 lens epithelium samples from cataract patients | HLE-B3 | WEE2, MAP3K2, MAP4K3, STK39, DFFB132, MAPK14, ANKRD6, RAD1, ATG12, SGT8, MAP3K1, YES1, RB1CC1, BCL2L2, EDNRB, WEE1, FER, PAK7, DCLR1C, UBXN2A, RAD18, PARP3, SLK, ATG2B, TMX3, BTBD3, TMX1, GPR37, CDC7, PPP2CA, IRR3, TP63, RHD, FRK, CXL13, POLR2D, GPX8, ITPR1, TLR4, SLK, UBE2N, SRPK2, CUL4B, TMX4, NBEAL1, CD226, CCL11, PIK3CA, DDB1, NLK | – | H2O2 treatment could overexpress miR-630 and correlated with nuclear opacity and progression of age-related nuclear cataract | [53] |
| Cataract       | Up                | Lens capsules from 25 cataract patients and 25 normal controls | SRA01/04 | EZF3, Bax, cleaved caspase 3, Bcl-2, N-cadherin, vimentin, and α-SMA, E-cadherin | Axon guidance pathway | miR-630 in partnership with miR-378a-5p and by EZF3 targeting inhibited cell growth and EMT but induced cell death | [55] |
Table 4 (continued)

| Type of disease          | Expression pattern | Samples                                                                 | Cell lines               | Downstream targets       | Related molecules and pathways | Function                                                                                      | Refs. |
|--------------------------|--------------------|------------------------------------------------------------------------|--------------------------|--------------------------|--------------------------------|---------------------------------------------------------------------------------------------|-------|
| Vitiligo                 | Down               | Peripheral blood of 5 vitiligo patients and 5 non-vitiligo cases       | –                        | –                        | –                              | miR-630 was identified as a differential expressed miRNA in vitiligo                        | [56]  |
| Heterotopic ossification (HO) | Down              | Sample of ectopic bone and serum from 146 HO cases, serums sample from 292 patients without HO after taking arthrolysis (control 1), and 292 patients with fracture healing (control 2)/mice | HD-MVEC, and 293T        | Slug, osteocalcin, osteopontin and Runx2, VE-cadherin, occluding, N-cadherin, and vimentin | –                              | Suppression of endothelial–mesenchymal transition by miR-630 via targeting slug could be involved in the formation of ectopic bone in HO | [57]  |
Abbreviations
miRNA: MicroRNA; circRNA: Circular RNA; ANCT: Adjacent non-cancerous tissue; NPC: Nasopharyngeal carcinoma; EMT: Epithelial–mesenchymal transition; RCC: Renal cell carcinoma; MV: Multiple myeloma; CRC: Colorectal cancer; ALL: Acute lymphoblastic leukemia; OC: Ovarian cancer; PCa: Prostate cancer; HCC: Hepatocellular carcinoma; PTC: Papillary thyroid carcinoma; NSCLC: Non-small cell lung cancer; GC: Gastric cancer; ESCC: Esophageal squamous cell carcinoma; CC: Cervical cancer; CDK: Cyclin-dependent kinase; BC: Breast cancer; IgAN: IgA nephropathy; HO: Heterotopic ossification; ED: Endothelial dysfunction; NEF: Normal endothelial function; OB: Obese; OSA: Obstructive sleep apnea; GEO: Gene expression omnibus; BCLC: Barcelona-clinic liver cancer.

Acknowledgements
Not applicable.

Authors’ contributions
SGF wrote the draft and revised it. SK collected the data and designed the tables and figures. All authors read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent forms were obtained from all study participants. The study protocol was approved by the ethical committee of Shahid Beheshti University of Medical Sciences.

Consent of publication
Not applicable.

Competing interests
The authors declare they have no competing interests.

Author details
1 Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. 2 Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Received: 21 November 2021   Accepted: 24 February 2022
Published online: 05 March 2022

References
1. Hussen BM, Hidayat HJ, Salihi A, Sabir DK, Taheri M, Ghafoori-Fard S. MicroRNA: a signature for cancer progression. Biomed Pharmacother. 2021;138:111528.
2. Ghafoori-Fard S, Shoori E, Bahroudi Z, Abak A, Majidpoor J, Taheri M. An update on the role of miR-124 in the pathogenesis of human disorders. Biomed Pharmacother. 2021;135:111198.
3. Ghafoori-Fard S, Bahroudi Z, Shoori E, Abak A, Ahin M, Taheri M. microRNA-140-5p/miR-140-3p: a miRNA with diverse roles in human diseases. Biomed Pharmacother. 2021;135:111256.
4. Ghafoori-Fard S, Khoshbakhht T, Hussen BM, Taheri M, Samadian M. A review on the role of miR-1290 in cell proliferation, apoptosis and invasion. Front Mol Biosci. 2021;8:763338.
5. Macfarlane L-A, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537–61.
6. Ghafoori-Fard S, Khoshbakhht T, Hussen BM, Kadkhoda S, Taheri M, Tafreshinejad A. A review on the role of miR-149-5p in the carcinogenesis. Int J Mol Sci. 2021;23(1):415.
7. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):500–24.
8. Zhao JJ, Chen PJ, Duan RQ, Li KJ, Wang YZ, Li Y. miR-630 functions as a tumor oncogene in renal cell carcinoma. Arch Med Sci. 2016;12(3):473–8.
9. Zhang L, Feng G, Zhang X, Ding Y, Wang X. microRNA-630 promotes cell proliferation and inhibits apoptosis in the HCT116 human colorectal cancer cell line. Mol Med Rep. 2017;16(4):4843–8.
10. Garehdeghiz Z, Obeidi N, Rustami yazigu S, Khamsipour G. Overexpression of microRNA-630 in acute leukemia T-cell line. Iran J Pediatr Hematol Oncol. 2020;10(3):159–72.
11. Zhang S, Zhang JJ, Lu LJ, Wang CH, Wang LH. miR-630 promotes epithelial ovarian cancer proliferation and invasion via targeting KLF6. Eur Rev Med Pharmacol Sci. 2017;21(20):4542–7.
12. Zou YT, Gao J, Wang HL, Wang Y, Wang H, Li PL. Downregulation of microRNA-630 inhibits cell proliferation and invasion and enhances chemosensitivity in human ovarian carcinoma. Genet Mol Res. 2015;14(3):8766–77.
13. Valera VA, Parra-Medina R, Walter BA, Pinto P, Merino MJ. microRNA expression profiling in young prostate cancer patients. J Cancer. 2020;11(14):4106–14.
14. Zhang JW, Li Y, Zeng XC, Zhang T, Fu BS, Yi HM, et al. miR-650 overexpression in hepatocellular carcinoma tissues is positively correlated with alpha-feto protein. Med Sci Monit. 2015;21:667–73.
15. Chen WX, Zhang ZG, Ding ZY, Liang HF, Song J, Tan XL, et al. MicroRNA-630 suppresses tumor metastasis through the TGF-β-miR-630-Slug signaling pathway and correlates inversely with poor prognosis in hepatocellular carcinoma. Oncotarget. 2016;7(16):22674–86.
16. Li YH, Xu OL, He CJ, Pu HH, Liu JL, Wang Y. circMTDHA/miR-630/AEG-1 axis participates in the regulation of proliferation, migration, invasion, chemoresistance, and radioresistance of NSCLC. Mol Carcinog. 2020;59(2):141–53.
17. Song YF, Hong JF, Liu DL, Lin QA, Lan XF, Lai GX. miR-630 targets LMO3 to regulate cell growth and metastasis in lung cancer. Am J Transl Res. 2015;7(7):1271–9.
18. Zhou L, Zhang H, Li C, Zhang G, Song X, Liu J. MicroRNA-630 acts as a prognostic marker in gastric cancer and its role in cell migration and invasion. Int J Clin Exp Pathol. 2017;10:4946–9.
19. Zhang Y, Liu H, Li W, Yu J, Li J, Shen Z, et al. CircRNA_100269 is downregulated in gastric cancer and suppresses tumor cell growth by targeting miR-630. Aging (Albany NY). 2017;9(6):1585–94.
20. Feng J, Wang X, Zhu W, Chen S, Feng C. MicroRNA-630 suppresses epithelial-to-mesenchymal transition by regulating FoxM1 in gastric cancer cells. Biochemistry. 2017;82(6):707–14.
21. Lin Y, Deng Q, Zhan M, Jiang F. A plasma long noncoding RNA signature for early detection of lung cancer. Transl Oncol. 2018;11(5):1225–31.
22. Zhou X, Zhou W, Li D, Chang A, Wang Y, Wu Y, et al. Plasma microRNA expression signature involving miR-548q, miR-630 and miR-940 as biomarkers for nasopharyngeal carcinoma detection. Cancer Biomark. 2018;23(4):579–87.
23. Li X, Lin Y, Yang X, Wu X, He X. Long noncoding RNA H119 regulates EZH2 expression by interacting with miR-630 and promotes cell invasion in nasopharyngeal carcinoma. Biochem Biophys Res Commun. 2016;473(4):913–9.
24. Qu X, Zhao M, Wu S, Yu W, Xu J, et al. Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol (Northwood, London, England). 2014;31(10):219.
25. Zhao X, Ren Y, Cui N, Wang X, Cui Y. Identification of key microRNAs and their targets in exosomes of pancreatic cancer using bioinformatics analysis. Medicine. 2018;97(39):e12632.
26. Lyu Y-Y, Wang F-M, Yang X-M, Zhang C-C, Gu F, Luo T-J, et al. miR-630 acts as a tumor suppressor in cervical cancer and inhibits epithelial–mesenchymal transition in cervical cancer. Int J Clin Exp Pathol. 2017;10:972–83.
27. Ge B, Liu H, Liang Q, Shang L, Wang T, Ge S. Oxytocin facilitates the proliferation, migration and osteogenic differentiation of human periodontal ligament stem cells in vitro. Arch Oral Biol. 2019;99:126–33.
28. Zhou C-X, Wang C-L, Yu A-L, Wang Q-Y, Zhan M-N, Tang J, et al. MicroRNA-630 suppresses breast cancer progression by targeting mediatorhin. Oncotarget. 2016;7(2):1288.
29. Li GW, Yan X. Lower miR-630 expression predicts poor prognosis of osteosarcoma and promotes cell proliferation, migration and invasion by targeting PSMC2. Eur Rev Med Pharmacol Sci. 2019;23(5):1915–25.

30. Pan XM, He XY, Yang YL, Jia WJ, Yang ZQ, Yan D, et al. MiR-630 inhibits papillary thyroid carcinoma cell growth, metastasis, and epithelial-mesenchymal transition by suppressing AK2/STAT3 signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(6):2453–60.

31. Liu X, Wu W, Zhang S, Tan W, Qu Y, Liao K, et al. Effect of miR-630 expression on esophageal cancer cell invasion and migration. J Clin Lab Anal. 2021;35(6):e23815.

32. Jin L, Yi J, Gao Y, Han S, He Z, Chen L, et al. MiR-630 inhibits invasion and metastasis in esophageal squamous cell carcinoma. Acta Biochem Biophys Sin. 2016;48(9):810–9.

33. Zhao JJ, Chen PJ, Duan RQ, Li KJ, Wang YZ, Li Y. Upregulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival. Int J Clin Exp Pathol. 2014;7(6):3318–23.

34. Chen MJ, Wu DW, Wang GC, Wang YC, Chen CY, Lee H. MicroRNA-630 may confer favorable cisplatin-based chemotherapy and clinical outcomes in non-small cell lung cancer by targeting Bcl-2. Oncotarget. 2018;9(17):13758–67.

35. Chu D, Zhao Z, Li Y, Li J, Zheng J, Wang W, et al. Increased microRNA-630 expression is associated with gastric cancer progression. PLoS ONE. 2014;9(5):e90526.

36. Chen L, Chen L, Qin Z, Lei J, Ye S, Zeng K, et al. Upregulation of miR-489-3p and miR-630 inhibits oxaliplatin uptake in renal cell carcinoma by targeting OCT2. Acta Pharm Sin B. 2019;9(5):1008–20.

37. Wu DW, Wang YC, Wang L, Chen CY, Lee H. A low microRNA-630 expression confers resistance to tyrosine kinase inhibitors in EGFR-mutated lung adenocarcinomas via miR-630/YAP1/ERK feedback loop. Theranostics. 2018;8(5):1256–69.

38. WangZY, Zhang W, Yang JJ, Song DK, Wei JX. Expression of microRNA-630 in bladder urothelial carcinoma and its clinical significance. J Huazhong Univ Sci Technol Med Sci. 2016;36(5):705–9.

39. Chu D, Zheng J, Li J, Li Y, Zhang J, Zhao Q, et al. MicroRNA-630 is a prognostic marker for patients with colorectal cancer. Tumour Biol. 2014;35(10):9787–92.

40. Galluzzi L, Morelli E, Vitale I, Kepp O, Senovilla L, Criollo A, et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res. 2014;70(5):1793–803.

41. Zhang Y, Yu J, Liu H, Ma W, Yan L, Wang J, et al. Novel epigenetic CREB-miR-630 signaling axis regulates radiosensitivity in colorectal cancer. PLoS ONE. 2015;10(8):e013870.

42. Eoh KJ, Lee SH, Kim HJ, Lee JY, Kim SW, et al. MicroRNA-630 inhibitor sensitizes chemoresistant ovarian cancer to chemotherapy by enhancing apoptosis. Biochem Biophys Res Commun. 2018;497(2):513–20.

43. Corcoran C, Rani S, Breslin S, Gogarty M, Ghobrial IM, Crown J, et al. miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer. 2014;13:71.

44. Huan LC, Wu JC, Chiu BH, Chen CH, Ma N, Chang CY, et al. MicroRNA regulation of DNA repair gene expression in 4-aminobiphenyl-treated HepG2 cells. Toxicology. 2014;322:69–77.

45. Cao JX, Li Y, Qi J, An GS, Mao ZB, Jia HT, et al. MiR-630 inhibits proliferation by targeting CDC7 kinase, but maintains the apoptotic balance by targeting multiple modulators in human lung cancer A549 cells. Cell Death Dis. 2014;5(9):e1426.

46. Sakurai MA, Ozaki Y, Okuzaki D, Naito Y, Sasakura T, Okamoto A, et al. Gfribnid and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630. PLoS ONE. 2014;9(6):e100124.

47. Farhana L, Dawson MJ, Murshed F, Das JK, Rishi AK, Fontana JA. Upregulation of miR-150a and miR-630 induces apoptosis in pancreatic cancer cells by targeting IGFR-1. PLoS ONE. 2013;8(5):e61015.

48. Zhang L, Wang C, Xue ZX. Inhibition of miR-630 enhances the cell resistance to radiation by directly targeting CDC14A in human glioma. Am J Transl Res. 2017;9(3):1255–65.

49. Rupaimoole R, Ivan C, Yang D, Ghapure KM, Wu SY, Pecot CV, et al. Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. Oncogene. 2016;35(33):4312–20.